Erkang Fan Selected Research

calcium-dependent protein kinase

1/2019	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.
1/2018	7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
1/2017	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
12/2016	Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.
1/2016	Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
3/2014	Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes.
10/2013	A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erkang Fan Research Topics

Disease

10	Cryptosporidiosis 01/2021 - 10/2013
9	Infections 01/2020 - 05/2011
7	Malaria 11/2014 - 01/2008
5	Toxoplasmosis 01/2021 - 03/2012
4	African Trypanosomiasis (Nagana) 01/2015 - 07/2012
2	Giardiasis 01/2022 - 01/2020
2	Parasitic Diseases (Parasitic Disease) 01/2020 - 09/2017
2	Cysts 01/2020 - 10/2015
2	Cardiotoxicity 01/2019 - 01/2016
2	Brucellosis (Malta Fever) 01/2016 - 01/2016
2	Cholera 05/2008 - 11/2002
1	Stillbirth 09/2020
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2020
1	Coinfection 01/2020
1	Tuberculosis (Tuberculoses) 01/2018
1	Gram-Positive Bacterial Infections 11/2017
1	Visceral Leishmaniasis (Kala Azar) 07/2017
1	Persistent Infection 12/2016
1	Encephalomyelitis (Myeloencephalitis) 12/2016
1	Drug-Related Side Effects and Adverse Reactions 08/2015
1	Neglected Diseases 01/2015
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 10/2013
1	Growth Disorders 10/2013
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2011

Drug/Important Bio-Agent (IBA)

12	Pharmaceutical PreparationsIBA 01/2021 - 09/2008
10	Phosphotransferases (Kinase)IBA 01/2022 - 12/2016
8	Methionine-tRNA LigaseIBA 01/2020 - 05/2011
7	calcium-dependent protein kinaseIBA 01/2019 - 10/2013
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2008
4	EnzymesIBA 01/2018 - 10/2012
3	CalciumIBA 12/2016 - 08/2012
3	LigandsIBA 07/2009 - 11/2002
2	Protein Kinases (Protein Kinase)IBA 09/2017 - 12/2016
2	bumped kinase inhibitor 1294IBA 10/2015 - 06/2014
2	Antiparasitic Agents (Antiparasitics)IBA 08/2015 - 07/2013
2	Antimalarials (Antimalarial Agents)IBA 11/2014 - 01/2014
2	Cholera ToxinIBA 05/2008 - 11/2002
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2021
1	Fertility AgentsIBA 09/2020
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2020
1	Azithromycin (Zithromax)FDA LinkGeneric 01/2020
1	nanolucIBA 01/2020
1	LuciferasesIBA 01/2020
1	pyrrolopyrimidineIBA 01/2019
1	nitazoxanide (NTZ)FDA Link 01/2019
1	imidazopyridineIBA 01/2019
1	AminesIBA 01/2018
1	Adenine FDA LinkGeneric 01/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2017
1	BKI-1553IBA 12/2016
1	Ether (Diethyl Ether)IBA 01/2016
1	artemisinin (artemisinine)IBA 01/2014
1	Ligases (Synthetase)IBA 05/2013
1	Transfer RNA (tRNA)IBA 05/2013
1	aminoquinoloneIBA 10/2012
1	Methionine (L-Methionine)FDA Link 10/2012
1	methioninyl adenylateIBA 10/2012
1	Urea (Carbamide)FDA LinkGeneric 07/2012
1	NucleosidesIBA 01/2011
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2011
1	Reverse Transcriptase InhibitorsIBA 01/2011
1	Adenosine DeaminaseIBA 09/2008
1	Bacterial ToxinsIBA 11/2002

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2011
1	Aftercare (After-Treatment) 12/2016
1	Highly Active Antiretroviral Therapy (HAART) 01/2011